[News Brief] HUYABIO Reports Positive Phase 3 Results for Advanced Melanoma Therapy
HUYABIO International has announced positive topline results from its global Phase 3 clinical trial evaluating HBI-8000 in combination with nivolumab as a first-line treatment for patients with advanced melanoma. This…
[News Brief] Innovent and Spero License Anti-CD40L Antibody for Autoimmune Diseases
Innovent Biologics and Spero Therapeutics have entered into an exclusive licence agreement for IBI355 (SP001), a Phase 2-ready third-generation Fc-silent anti-CD40L antibody, for the development and commercialisation of treatments for…
[News Brief] Halozyme and Incyte Partner on Subcutaneous Drug Delivery for Blood Cancer Therapy
Halozyme Therapeutics has entered into a global collaboration and licence agreement with Incyte to develop subcutaneous formulations of INCA033989, a monoclonal antibody for mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms (MPNs), using…
[News Brief] Sai Parenterals Renews Australian OTC Supply Agreement
Sai Parenterals’ Australian subsidiary, Noumed Pharmaceuticals, has renewed an exclusive over-the-counter (OTC) medicines supply agreement with one of Australia’s leading pharmacy chains. The 7.5-year contract covers the supply of an…
[News Brief] AstraZeneca Secures Global Licensing Rights to Zegfrovy for Lung Cancer
AstraZeneca has entered into an exclusive global licensing agreement with Dizal Pharmaceutical to acquire worldwide development and commercialisation rights for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for non-small cell lung…
[News Brief] Merck Opens BioReliance Testing Facility in Germany
Merck has opened a 2,000-square-metre BioReliance testing facility at its headquarters in Darmstadt, Germany. The site provides commercial drug substance, drug product release, and Good Manufacturing Practice (GMP)-compliant stability testing…
[News Brief] MAXONA Pharmaceuticals Receives FDA Clearance for Pain Therapy Trial
MAXONA Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to proceed with a Phase 2 clinical trial of its…
[News Brief] Insilico Medicine Initiates Phase III Trial for AI-Discovered IPF Drug Candidate
Insilico Medicine has initiated a Phase III clinical trial evaluating Rentosertib (formerly ISM001-055/INS018_055), an orally administered small-molecule TNIK inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). This summary is…
[News Brief] BioMed X and Boehringer Ingelheim Expand XSeed Labs Partnership
BioMed X and Boehringer Ingelheim have expanded their XSeed Labs collaboration by launching a new research team to advance next-generation biologics for retinal diseases. This summary is based on a…
[News Brief] West Introduces Synchrony Prefillable Syringe System in Southeast Asia
West Pharmaceutical Services, Inc. has launched its Synchrony™ prefillable syringe (PFS) system for biologics and vaccines across five Southeast Asian markets. This summary is based on a news article published…
[News Brief] Lynk Pharmaceuticals Doses First Patient in LNK01004 Vitiligo Trial
Lynk Pharmaceuticals Co., Ltd. has initiated dosing in its Phase II clinical trial evaluating LNK01004, a topical pan-JAK inhibitor, for the treatment of adult patients with non-segmental vitiligo. This summary…
[News Brief] Senhwa Biosciences Secures NT$500 Million Share Purchase Agreement with GEM
Senhwa Biosciences, Inc. has entered into a share purchase agreement with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited involving a commitment of up to NT$500 million. This…
[News Brief] Godavari Biorefineries Validates European Patent for Anti-Cancer Molecule
Godavari Biorefineries has announced the successful validation of its European patent for a novel anti-cancer molecule in Spain, the United Kingdom, and as a unitary patent across multiple European Union…
[News Brief] DoH Abu Dhabi, AstraZeneca, and PureHealth Establish Rare Diseases Centre
The Department of Health – Abu Dhabi (DoH), AstraZeneca, and PureHealth have signed a Memorandum of Understanding (MoU) to activate a Rare Diseases Centre of Excellence in Abu Dhabi. This…
[News Brief] Takeda and Indonesian Government Partner to Advance Plasma Healthcare
Takeda and the Indonesian Government have announced a multi-phased collaboration to strengthen the country’s plasma ecosystem and expand access to plasma-derived medicinal products (PDMPs). This summary is based on a…
[News Brief] Bristol Myers Squibb Names Singapore as Pan Asia Hub
Bristol Myers Squibb (BMS) has recognised Singapore as its new Pan Asia Cluster (PAC) hub, supported by the Singapore Economic Development Board, as part of its regional operations. This summary…
[News Brief] UCL and Eisai Extend Neurodegenerative Disease Research Partnership
University College London (UCL) and Eisai Co., Ltd. have signed a new agreement extending their collaboration in drug discovery and development for neurodegenerative diseases for a further five years, through…
[News Brief] Cadila Pharmaceuticals and Wellesta Holdings Sign Joint Venture MoU
Cadila Pharmaceuticals and Wellesta Holdings have signed a memorandum of understanding to establish a strategic joint venture focused on commercialising pharmaceutical and healthcare products across South-East Asia and selected international…
[News Brief] Abbisko Expands R&D Collaboration with Eli Lilly
Abbisko Therapeutics has entered into a strategic research collaboration and licence agreement with Eli Lilly and Company to discover and develop innovative medicines across multiple disease targets. This summary is…
[News Brief] Haisco Licenses Drug Candidates to Nuvectis
Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with US-based biotechnology company Nuvectis for two internally developed clinical-stage drug candidates across selected global markets. This summary is based…
[News Brief] CeleCor Completes FDA Application for Heart Attack Drug
CeleCor Therapeutics has completed its New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) for investigational heart attack treatment zalunfiban following positive Phase III study results.…
[News Brief] AnHorn Medicines Secures Regulatory Clearances for AH-008
AnHorn Medicines has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration and Index Case designation from Taiwan’s Center for Drug Evaluation for AH-008, a candidate…
[News Brief] Sonire Therapeutics Receives NEDO Support for HIFU Platform
Sonire Therapeutics KK has received funding through Japan’s New Energy and Industrial Technology Development Organization (NEDO) Deep-Tech Startups Support Program to advance its ultrasound-guided High-Intensity Focused Ultrasound (HIFU) therapy platform.…
[News Brief] Innovent Biologics and Pfizer Sign Oncology Collaboration
China-based Innovent Biologics and Pfizer have entered a global licensing and collaboration agreement to research and develop twelve early-stage cancer medicine programmes. This summary is based on a news article…
[News Brief] Everest Medicines Licenses Kidney Disease Therapy to Travere
China-based Everest Medicines has entered an exclusive licensing and collaboration agreement with US-based Travere Therapeutics for the development and commercialisation of civorebrutinib, an investigational oral BTK inhibitor for rare immune-mediated…
[News Brief] FDA Approves Tremfya Label Expansion for Psoriatic Arthritis
The US Food and Drug Administration (FDA) has approved a label expansion for Tremfya (guselkumab) to include evidence for inhibition of progression of structural joint damage in adults with active…
[News Brief] Pfizer Receives FDA Approval for Expanded Hympavzi Use
Pfizer has received US Food and Drug Administration (FDA) approval for an expanded indication of Hympavzi (marstacimab-hncq) for adults and paediatric patients aged six years and older with haemophilia A…
[News Brief] Everest Medicines Licences Sumecigrel for Asia-Pacific Development
Everest Medicines has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co. for the development, registration and commercialisation of Sumecigrel across the Asia-Pacific region. This summary is based…
[News Brief] Simcere Pharma Enters Research Collaboration With Stanford Medicine
Simcere Pharmaceutical Group Limited has entered a research collaboration with Stanford University School of Medicine to develop potential treatments for idiopathic pulmonary fibrosis (IPF) using small-molecule candidates. This summary is…
[News Brief] Legend Biotech to Present LB2501 Data at EHA 2026
Legend Biotech Corporation has announced that it will present preliminary Phase 1 clinical data for its investigational LB2501 therapy during a late-breaking oral session at the European Hematology Association Congress…
[News Brief] CordenPharma Agrees to Acquire AmbioPharm
CordenPharma has entered into an agreement to acquire AmbioPharm, a US-headquartered contract development and manufacturing organisation (CDMO), to expand its global peptide Active Pharmaceutical Ingredient (API) manufacturing capabilities. This summary…
[News Brief] Australia Approves OncoSil™ Device for Pancreatic Cancer
Australia’s Therapeutic Goods Administration (TGA) has approved the OncoSil™ medical device for use in patients with locally advanced pancreatic cancer. This summary is based on a news article issued by…
[News Brief] AstraZeneca Enters Licensing Agreement with CSPC Pharmaceuticals
AstraZeneca has entered into a strategic collaboration with CSPC Pharmaceutical Group to obtain ex-China rights to a weight management portfolio comprising eight programmes targeting obesity and type 2 diabetes. This…
[News Brief] GSK Enters Strategic Collaboration with SBP Group
GSK plc has entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group), through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), to support the planned availability…
[News Brief] Amplexd Therapeutics Starts Phase 2 HPV Trial
Amplexd Therapeutics has received authorisation from the Hong Kong Department of Health to begin a Phase 2 trial of an epigallocatechin gallate (EGCg) vaginal suppository for precancerous cervical lesions linked…
[News Brief] Griffith University and Thermo Fisher Sign MoU for Research Collaboration
Griffith University and Thermo Fisher Scientific have signed a five-year Memorandum of Understanding (MoU) to support collaboration in health, biotechnology and translational research within the Gold Coast Health & Knowledge…
[News Brief] WHO Prequalifies First Malaria Treatment for Newborns
The World Health Organization has prequalified Coartem Baby (artemether-lumefantrine), the first malaria treatment specifically developed for newborns and young infants weighing between 2kg and 5kg for uncomplicated malaria. This summary…
[News Brief] Cirrus Therapeutics Expands to Singapore with R&D Site
Cirrus Therapeutics has expanded into Singapore with a new R&D site and formed a partnership with A*STAR to advance ophthalmic therapies targeting chronic blinding diseases in the Asia-Pacific region. This…
[News Brief] ImmunoScape Signs MoU for US Cancer Clinical Trial
ImmunoScape has signed a Memorandum of Understanding with a US-based cancer centre to launch an investigator-initiated clinical trial targeting WT1-positive solid tumours using its TCR-based immunotherapy platform. This summary is…
[News Brief] United Labs and Novo Nordisk Announce Phase 2 UBT251 Results
The United Laboratories International Holdings Limited and Novo Nordisk A/S announced topline results from a Chinese phase 2 trial of UBT251, reporting up to 19.7% mean weight loss after 24…
[News Brief] OneSource-Hikma Partnership Secures Approval for Generic Ozempic in Saudi Arabia
OneSource Specialty Pharma has received regulatory approval in Saudi Arabia to commercialise a generic version of Ozempic® (semaglutide) in collaboration with Hikma Pharmaceuticals. This summary is based on a report…
[News Brief] ImmunityBio to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Treatment
ImmunityBio has partnered with Biopharma and Cigalah Healthcare to commercialise ANKTIVA® (nogapendekin alfa inbakicept) in Saudi Arabia for bladder and lung cancer treatment. This summary is based on a report…
[News Brief] Pharmapack Announces Expansion to Asia with Singapore Event in November 2026
Pharmapack Europe has announced the launch of a new Pharmapack Asia event in Singapore, slated for November 2026, offering a platform for the pharmaceutical packaging and drug-delivery industry to connect…
[News Brief] GSK: Arexvy Linked to Lower RSV-Related Cardiopulmonary Risks
GSK has published findings indicating its respiratory syncytial virus (RSV) vaccine Arexvy was associated with reduced risks of certain severe cardiopulmonary outcomes, including heart attack, stroke and exacerbations of COPD…
[News Brief] ViiV Healthcare Reports Better Outcomes for Long-Acting HIV Therapy
ViiV Healthcare has reported that final data from the LATITUDE phase III trial show its long-acting injectable regimen, Cabenuva (cabotegravir + rilpivirine), maintained viral suppression more effectively than daily oral…
[News Brief] Otsuka Pharmaceutical Co., Ltd. Announces FDA Priority Review of Centanafadine NDA for ADHD
Otsuka has stated that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for centanafadine, an investigational once-daily extended-release treatment for attention-deficit…
[News Brief] Novo Nordisk Secures EU Approval for 7.2 mg Wegovy Dose
The European Commission has approved a 7.2 mg once-weekly maintenance dose of Wegovy® (semaglutide) for adults with obesity across all 27 European Union countries, providing an additional option for patients…
[News Brief] Sanofi’s Tzield Accepted for Priority Review in the US for Young Children with Stage 2 Type 1 Diabetes
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics licence application for Tzield (teplizumab‑mzwv) to expand its use to children…
[News Brief] Takeda Releases Phase 3 Data for Zasocitinib in Plaque Psoriasis
Takeda has published results from its Phase 3 clinical trials for Zasocitinib, an oral treatment for moderate-to-severe plaque psoriasis. This summary is based on a press release issued by Takeda.